Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children

Hislop A.A., Moledina S., Foster H., Schulze-Neick I., Haworth S.G.

Source: Eur Respir J 2011; 37: 70-77

Journal Issue: July

Disease area: Pulmonary vascular diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Hislop A.A., Moledina S., Foster H., Schulze-Neick I., Haworth S.G.. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J 2011; 37: 70-77

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Pulmonary arterial hypertension in children Source: Eur Respir J 2003; 21: 155-176 Year: 2003
Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012
Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010
When is pulmonary hypertension not pulmonary hypertension? Source: Eur Respir J 2001; 18: Suppl. 33, 522s Year: 2001
Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009
Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease Source: Eur Respir Rev 2009; 18: 154-161 Year: 2009
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology Source: Eur Respir Rev 2009; 19: 59-63 Year: 2010
Pulmonary arterial hypertension: a comparison between children and adults Source: Eur Respir J 2011; 37: 665-677 Year: 2011
Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005
Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005
Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006
The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018
The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012
The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017
The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014
The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006
Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 770 Year: 2009